- Home
- EOSE vs LQDA Comparison
EOSE vs LQDA Comparison
Compare EOSE & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- LQDA
- Stock Information
- Founded
- EOSE 2008
- LQDA 2004
- Country
- EOSE United States
- LQDA United States
- Employees
- EOSE N/A
- LQDA N/A
- Industry
- EOSE Industrial Machinery/Components
- LQDA Biotechnology: Pharmaceutical Preparations
- Sector
- EOSE Miscellaneous
- LQDA Health Care
- Exchange
- EOSE Nasdaq
- LQDA Nasdaq
- Market Cap
- EOSE 1.6B
- LQDA 1.7B
- IPO Year
- EOSE N/A
- LQDA 2018
- Fundamental
- Price
- EOSE $6.32
- LQDA $26.84
- Analyst Decision
- EOSE Strong Buy
- LQDA Strong Buy
- Analyst Count
- EOSE 3
- LQDA 10
- Target Price
- EOSE $6.50
- LQDA $31.40
- AVG Volume (30 Days)
- EOSE 12.6M
- LQDA 3.2M
- Earning Date
- EOSE 07-30-2025
- LQDA 08-12-2025
- Dividend Yield
- EOSE N/A
- LQDA N/A
- EPS Growth
- EOSE N/A
- LQDA N/A
- EPS
- EOSE N/A
- LQDA N/A
- Revenue
- EOSE $33,800,000.00
- LQDA $19,322,000.00
- Revenue This Year
- EOSE $945.82
- LQDA $190.73
- Revenue Next Year
- EOSE $195.86
- LQDA $421.01
- P/E Ratio
- EOSE N/A
- LQDA N/A
- Revenue Growth
- EOSE 128.49
- LQDA 30.20
- 52 Week Low
- EOSE $2.06
- LQDA $8.75
- 52 Week High
- EOSE $7.36
- LQDA $28.00
- Technical
- Relative Strength Index (RSI)
- EOSE 56.22
- LQDA 74.95
- Support Level
- EOSE $5.77
- LQDA $26.47
- Resistance Level
- EOSE $6.40
- LQDA $27.88
- Average True Range (ATR)
- EOSE 0.39
- LQDA 1.44
- MACD
- EOSE -0.06
- LQDA 0.35
- Stochastic Oscillator
- EOSE 48.25
- LQDA 87.08
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.